Three‐year clinical outcome of biodegradable hybrid polymer Orsiro sirolimus‐eluting stent and the durable biocompatible polymer Resolute Integrity zotarolimus‐eluting stent: A randomized controlled trial

Newer Generation Ultra-Thin Strut Drug-Eluting Stents versus Older Second-Generation Thicker Strut Drug-Eluting Stents for Coronary Artery Disease: A Meta-Analysis of Randomized Trials

(2018) Sripal Bangalore et al.   CIRCULATION

Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document

(2018) Hector M. Garcia-Garcia et al.   CIRCULATION

Long-term safety of bioresorbable scaffolds: insights from a network meta-analysis including 91 trials

(2018) Si-Hyuck Kang et al.   EuroIntervention

Bioresorbable Scaffolds in Coronary Intervention: Unmet Needs and Evolution

(2018) Davide Capodanno   Korean Circulation Journal

2018 ESC/EACTS Guidelines on myocardial revascularization

(2018) Franz-Josef Neumann et al.   EUROPEAN HEART JOURNAL

Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents versus Thin Durable Polymer Everolimus-Eluting Stents: BIOFLOW V 2-Year Results

(2018) David E. Kandzari et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Fourth Universal Definition of Myocardial Infarction (2018)

(2018) Kristian Thygesen et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial

(2018) Thomas Pilgrim et al.   LANCET

Thin composite wire strut, durable polymer-coated (Resolute Onyx) versus ultrathin cobalt–chromium strut, bioresorbable polymer-coated (Orsiro) drug-eluting stents in allcomers with coronary artery disease (BIONYX): an international, single-blind, randomised non-inferiority trial

(2018) Clemens von Birgelen et al.   LANCET

Randomized Multicenter Trial Investigating Angiographic Outcomes of Hybrid Sirolimus-Eluting Stents With Biodegradable Polymer Compared With Everolimus-Eluting Stents With Durable Polymer in Chronic Total Occlusions

(2017) Koen Teeuwen et al.   JACC-Cardiovascular Interventions

10-Year Clinical Outcome After Randomization to Treatment by Sirolimus- or Paclitaxel-Eluting Coronary Stents

(2017) Anders M. Galløe et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial

(2017) David E Kandzari et al.   LANCET

Angiographic outcomes of Orsiro biodegradable polymer sirolimus-eluting stents and Resolute Integrity durable polymer zotarolimus-eluting stents: results of the ORIENT trial

(2017) Si-Hyuck Kang et al.   EuroIntervention

2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery

(2016) Glenn N. Levine et al.   CIRCULATION

Failure Mechanisms and Neoatherosclerosis Patterns in Very Late Drug-Eluting and Bare-Metal Stent Thrombosis

(2016) Daisuke Nakamura et al.   Circulation-Cardiovascular Interventions

Ten-year clinical outcomes of first-generation drug-eluting stents: the Sirolimus-Eluting vs. Paclitaxel-Eluting Stents for Coronary Revascularization (SIRTAX) VERY LATE trial

(2016) Kyohei Yamaji et al.   EUROPEAN HEART JOURNAL

Stent Thrombosis With Drug-Eluting Stents and Bioresorbable Scaffolds

(2016) Si-Hyuck Kang et al.   JACC-Cardiovascular Interventions

Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial

(2016) Clemens von Birgelen et al.   LANCET

Comparison of a Novel Biodegradable Polymer Sirolimus-Eluting Stent With a Durable Polymer Everolimus-Eluting Stent: Results of the Randomized BIOFLOW-II Trial

(2015) S. Windecker et al.   Circulation-Cardiovascular Interventions

Neoatherosclerosis: overview of histopathologic findings and implications for intravascular imaging assessment

(2015) Fumiyuki Otsuka et al.   EUROPEAN HEART JOURNAL

Report of a European Society of Cardiology-European Association of Percutaneous Cardiovascular Interventions task force on the evaluation of coronary stents in Europe: executive summary

(2015) Robert A. Byrne et al.   EUROPEAN HEART JOURNAL

Zotarolimus-eluting durable-polymer-coated stent versus a biolimus-eluting biodegradable-polymer-coated stent in unselected patients undergoing percutaneous coronary intervention (SORT OUT VI): a randomised non-inferiority trial

(2015) Bent Raungaard et al.   LANCET

Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial

(2014) Thomas Pilgrim et al.   LANCET

Everolimus-eluting stents in patients undergoing percutaneous coronary intervention: Final 3-year results of the Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With de Novo Native Coronary Artery Lesions trial

(2013) Sorin J. Brener et al.   AMERICAN HEART JOURNAL

Coronary stents: novel developments

(2013) Giulio G Stefanini et al.   HEART

Angiographic and clinical comparison of novel Orsiro Hybrid sirolimus-eluting stents and Resolute Integrity zotarolimus-eluting stents in all-comers with coronary artery disease (ORIENT trial): study protocol for a randomized controlled trial

(2013) Joo Myung Lee et al.   Trials

Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial

(2012) Edoardo Camenzind et al.   LANCET

Histopathological comparison of biodegradable polymer and permanent polymer based sirolimus eluting stents in a porcine model of coronary stent implantation

(2012) Gerd Bayer et al.   THROMBOSIS AND HAEMOSTASIS

Stent Thrombogenicity Early in High-Risk Interventional Settings Is Driven by Stent Design and Deployment and Protected by Polymer-Drug Coatings

(2011) Kumaran Kolandaivelu et al.   CIRCULATION

Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial

(2009) Stefan James et al.   AMERICAN HEART JOURNAL

Five-Year Follow-Up After Sirolimus-Eluting Stent Implantation

(2009) Giora Weisz et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial

(2008) Stephan Windecker et al.   LANCET